特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
939095

ヒドロキシクロロキン:世界市場の展望(2018-2027年)

Hydroxychloroquine - Global Market Outlook (2018-2027)

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 140 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
ヒドロキシクロロキン:世界市場の展望(2018-2027年)
出版日: 2020年05月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 140 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のヒドロキシクロロキンの市場は予測期間中10.4%のCAGRで推移し、2018年の4130万米ドルから、2027年にはまでに1億62万米ドルの規模に成長すると予測されています。高齢者人口の増加や、第三世界の国々からのマラリア用薬剤への高い需要などの要因が同市場の成長を推進しています。しかし一方で、製品のリコールや製造販売の中止などの要因が市場のさらなる成長を妨げています。

当レポートでは、世界のヒドロキシクロロキンの市場を調査し、市場および製品の概要、市場成長への各種影響因子および市場機会の分析、タイプ・投薬経路・グレード・成分・用途・地域/主要国など各種区分別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向の分析

  • イントロダクション
  • 促進要因
  • 抑制要因
  • 市場機会
  • 脅威
  • 用途分析
  • 新興市場
  • Covid-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界のヒドロキシクロロキン市場:タイプ別

  • イントロダクション
  • タブレット
  • 注射剤

第6章 世界のヒドロキシクロロキン市場:投与経路別

  • イントロダクション
  • 経口
  • 静脈内注射

第7章 世界のヒドロキシクロロキン市場:グレード別

  • イントロダクション
  • 米国薬局方条約(USP)標準グレード
  • 医薬品規格グレード
  • 欧州薬局方(EP)標準グレード

第8章 世界のヒドロキシクロロキン市場:成分別

  • イントロダクション
  • 100 mg
  • 200 mg
  • 250 mg
  • 400 mg
  • 500 mg
  • 800 mg

第9章 世界のヒドロキシクロロキン市場:流通経路別

  • イントロダクション
  • 院内薬局
  • オンライン薬局
  • 専門薬局
  • 小売薬局
  • ホメオケア

第10章 世界のヒドロキシクロロキン市場:用途別

  • イントロダクション
  • マラリア
  • 関節リウマチ
  • エリテマトーデス
    • 全身性エリテマトーデス
    • 慢性円板状エリテマトーデス
  • 皮膚病変
  • COVID-19(新型コロナウイルス感染症)

第11章 世界のヒドロキシクロロキン市場: 地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第12章 主な展開

  • 契約・提携・協力・JV
  • M&A
  • 新製品の発売
  • 拡張
  • その他の主要戦略

第13章 企業プロファイル

  • Hikma Pharmaceuticals PLC
  • Cadila Healthcare Ltd
  • Ipca Laboratories Ltd
  • Novartis AG
  • Mylan N.V
  • Sanofi S.A
  • Taj Pharmaceuticals Ltd
  • Shanghai Pharmaceuticals Holding Co., Ltd
  • Torrent Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Zydus Cadila
図表

List of Tables

  • Table 1 Global Hydroxychloroquine Market Outlook, By Region (2017-2027) ($MN)
  • Table 2 Global Hydroxychloroquine Market Outlook, By Type (2017-2027) ($MN)
  • Table 3 Global Hydroxychloroquine Market Outlook, By Tablets (2017-2027) ($MN)
  • Table 4 Global Hydroxychloroquine Market Outlook, By Injection (2017-2027) ($MN)
  • Table 5 Global Hydroxychloroquine Market Outlook, By Route of Administration (2017-2027) ($MN)
  • Table 6 Global Hydroxychloroquine Market Outlook, By Oral (2017-2027) ($MN)
  • Table 7 Global Hydroxychloroquine Market Outlook, By Intravenous (2017-2027) ($MN)
  • Table 8 Global Hydroxychloroquine Market Outlook, By Grade (2017-2027) ($MN)
  • Table 9 Global Hydroxychloroquine Market Outlook, By United States Pharmacopeial Convention (USP) Standards Grade (2017-2027) ($MN)
  • Table 10 Global Hydroxychloroquine Market Outlook, By Pharmaceutical Standards Grade (2017-2027) ($MN)
  • Table 11 Global Hydroxychloroquine Market Outlook, By European Pharmacopoeia (EP) Standards Grade (2017-2027) ($MN)
  • Table 12 Global Hydroxychloroquine Market Outlook, By Strength (2017-2027) ($MN)
  • Table 13 Global Hydroxychloroquine Market Outlook, By 100 mg (2017-2027) ($MN)
  • Table 14 Global Hydroxychloroquine Market Outlook, By 200 mg (2017-2027) ($MN)
  • Table 15 Global Hydroxychloroquine Market Outlook, By 250 mg (2017-2027) ($MN)
  • Table 16 Global Hydroxychloroquine Market Outlook, By 400 mg (2017-2027) ($MN)
  • Table 17 Global Hydroxychloroquine Market Outlook, By 500 mg (2017-2027) ($MN)
  • Table 18 Global Hydroxychloroquine Market Outlook, By 800 mg (2017-2027) ($MN)
  • Table 19 Global Hydroxychloroquine Market Outlook, By Distribution Channel (2017-2027) ($MN)
  • Table 20 Global Hydroxychloroquine Market Outlook, By Hospital Pharmacy (2017-2027) ($MN)
  • Table 21 Global Hydroxychloroquine Market Outlook, By Online Pharmacy (2017-2027) ($MN)
  • Table 22 Global Hydroxychloroquine Market Outlook, By Speciality Drug Stores (2017-2027) ($MN)
  • Table 23 Global Hydroxychloroquine Market Outlook, By Retail Pharmacy (2017-2027) ($MN)
  • Table 24 Global Hydroxychloroquine Market Outlook, By Homeocare (2017-2027) ($MN)
  • Table 25 Global Hydroxychloroquine Market Outlook, By Application (2017-2027) ($MN)
  • Table 26 Global Hydroxychloroquine Market Outlook, By Malaria (2017-2027) ($MN)
  • Table 27 Global Hydroxychloroquine Market Outlook, By Rheumatoid arthritis (2017-2027) ($MN)
  • Table 28 Global Hydroxychloroquine Market Outlook, By Lupus Erythematosus (2017-2027) ($MN)
  • Table 29 Global Hydroxychloroquine Market Outlook, By Systemic Lupus Erythematosus (2017-2027) ($MN)
  • Table 30 Global Hydroxychloroquine Market Outlook, By Chronic Discoid Lupus Erythematosus (2017-2027) ($MN)
  • Table 31 Global Hydroxychloroquine Market Outlook, By Skin Lesions (2017-2027) ($MN)
  • Table 32 Global Hydroxychloroquine Market Outlook, By COVID-19 (2017-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次

According to Stratistics MRC, the Global Hydroxychloroquine Market is accounted for $41.30 million in 2018 and is expected to reach $100.62 million by 2027 growing at a CAGR of 10.4% during the forecast period. The rising geriatric population, and the high demand for the drug from third world nations for dealing with malarial are the major factors propelling the market growth. However, factors such as product recalls and discontinuation of drugs are hampering the market growth.

Hydroxychloroquine is a medication and analogue of chloroquine. It has antirheumatic as well as antimalarial properties. It has been used widely for the treatment of infectious as well as rheumatoid arthritis. It has been recognized that clinical use of hydroxychloroquine has significantly improve the treatment rate of patient suffering from the COVID-19. The growth of hydroxychloroquine enhanced by the growing cases of infectious diseases that majorly includes coronavirus and malaria and increase research and development activities. In addition, advances in the treatment options and presence of well-established healthcare facilities are some of the impacting factors for the demand of hydroxychloroquine drugs.

Based on the application, the COVID-19 segment is going to have a lucrative growth during the forecast period as this is a new condition and a large number of trials are conducted on the effectiveness of the medicine in treating the condition, it would contribute to the growth rate witnessed by this segment. The fact that a large number of patients with COVID-19 are admitted to hospitals for treatment results in high preference and dependence on this medicine, contributing to the market share held by this segment.

By geography, Asia Pacific is going to have a lucrative growth during the forecast period attributed to India being the leading producer of the drug and China being the largest exporter of the raw materials for the drug production. Apart from this, it is cost-effective drug in India costing nearly lesser than rupees three per tablet. Moreover, the drug has been advocated in countries like India as a measure to prevent the coronavirus in people who have been in contact with COVID positive persons and those falling in high risk zone. All these aforementioned aspects are likely to favorably leverage the growth of the Hydroxychloroquine market over the forecast period.

Some of the key players profiled in the Hydroxychloroquine Market include Hikma Pharmaceuticals PLC, Cadila Healthcare Ltd, Ipca Laboratories Ltd, Novartis AG , Mylan N.V, Sanofi S.A, Taj Pharmaceuticals Ltd , Shanghai Pharmaceuticals Holding Co., Ltd, Torrent Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd , Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, and Zydus Cadila.

Types Covered:

  • Tablets
  • Injection

Route of Administrations Covered:

  • Oral
  • Intravenous

Grades Covered:

  • United States Pharmacopeial Convention (USP) Standards Grade
  • Pharmaceutical Standards Grade
  • European Pharmacopoeia (EP) Standards Grade

Strengths Covered:

  • 100 mg
  • 200 mg
  • 250 mg
  • 400 mg
  • 500 mg
  • 800 mg

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Speciality Drug Stores
  • Retail Pharmacy
  • Homeocare

Applications Covered:

  • Malaria
  • Rheumatoid arthritis
  • Lupus Erythematosus
  • Skin Lesions
  • COVID-19

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hydroxychloroquine Market, By Type

  • 5.1 Introduction
  • 5.2 Tablets
  • 5.3 Injection

6 Global Hydroxychloroquine Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Intravenous

7 Global Hydroxychloroquine Market, By Grade

  • 7.1 Introduction
  • 7.2 United States Pharmacopeial Convention (USP) Standards Grade
  • 7.3 Pharmaceutical Standards Grade
  • 7.4 European Pharmacopoeia (EP) Standards Grade

8 Global Hydroxychloroquine Market, By Strength

  • 8.1 Introduction
  • 8.2 100 mg
  • 8.3 200 mg
  • 8.4 250 mg
  • 8.5 400 mg
  • 8.6 500 mg
  • 8.7 800 mg

9 Global Hydroxychloroquine Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Speciality Drug Stores
  • 9.5 Retail Pharmacy
  • 9.6 Homeocare

10 Global Hydroxychloroquine Market, By Application

  • 10.1 Introduction
  • 10.2 Malaria
  • 10.3 Rheumatoid arthritis
  • 10.4 Lupus Erythematosus
    • 10.4.1 Systemic Lupus Erythematosus
    • 10.4.2 Chronic Discoid Lupus Erythematosus
  • 10.5 Skin Lesions
  • 10.6 COVID-19

11 Global Hydroxychloroquine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Hikma Pharmaceuticals PLC
  • 13.2 Cadila Healthcare Ltd
  • 13.3 Ipca Laboratories Ltd
  • 13.4 Novartis AG
  • 13.5 Mylan N.V
  • 13.6 Sanofi S.A
  • 13.7 Taj Pharmaceuticals Ltd
  • 13.8 Shanghai Pharmaceuticals Holding Co., Ltd
  • 13.9 Torrent Pharmaceuticals Ltd
  • 13.10 Teva Pharmaceutical Industries Ltd
  • 13.11 Dr. Reddy's Laboratories Ltd
  • 13.12 Sun Pharmaceutical Industries Ltd
  • 13.13 Zydus Cadila
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.